Wegovy to Zepbound Conversion Chart: The Dose-Equivalent Framework and When Direct Conversion Fails

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• No published milligram-to-milligram conversion exists because semaglutide (Wegovy) and tirzepatide (Zepbound) activate different receptor combinations with different potencies
• The standard clinical approach starts tirzepatide at 2.5 mg regardless of prior semaglutide dose, then titrates based on tolerance and response
• Weight-loss equivalency data suggests Zepbound 10 mg produces similar outcomes to Wegovy 2.4 mg, but individual response varies by 30% or more
• Patients switching from Wegovy maintenance doses typically reach therapeutic effect at Zepbound 7.5 to 10 mg after 8 to 12 weeks of titration

Direct answer (40-60 words)

There is no direct milligram-to-milligram conversion between Wegovy (semaglutide) and Zepbound (tirzepatide) because they are different molecules acting on different receptors. The standard protocol starts tirzepatide at 2.5 mg regardless of prior semaglutide dose, then escalates every 4 weeks based on tolerance. Weight-loss equivalency data suggests Zepbound 10 mg approximates Wegovy 2.4 mg outcomes.

Table of contents

1. Why direct dose conversion doesn't exist
2. The weight-loss equivalency framework (what the trials show)
3. The standard switching protocol providers use
4. Dose-response comparison table: Wegovy vs Zepbound
5. What most articles get wrong about "equivalent doses"
6. The 3-pattern typology: how patients actually respond to the switch
7. Timing the switch: washout vs overlap strategies
8. Side effect profile differences that affect conversion strategy
9. When switching makes clinical sense (and when it doesn't)
10. The compounded tirzepatide consideration
11. FAQ
12. Sources

Why direct dose conversion doesn't exist

Wegovy contains semaglutide, a GLP-1 receptor agonist. Zepbound contains tirzepatide, a dual GLP-1 and GIP receptor agonist. The two molecules have different molecular weights (4,113 Da vs 4,813 Da), different receptor binding affinities, different half-lives (7 days vs 5 days), and fundamentally different mechanisms.

Semaglutide binds exclusively to GLP-1 receptors with 94% homology to native GLP-1. Tirzepatide binds both GLP-1 receptors (with lower affinity than semaglutide) and GIP receptors (with high affinity). The GIP receptor activation adds a second pathway for insulin secretion, glucagon suppression, and potentially adipocyte metabolism that semaglutide doesn't touch.

Because of the dual-receptor mechanism, you cannot calculate a direct conversion ratio. A 10 mg dose of tirzepatide is not "twice as strong" or "half as strong" as any specific semaglutide dose. The two drugs produce overlapping but non-identical effects through different pathways.

The FDA-approved titration schedules reflect this. Wegovy starts at 0.25 mg weekly and escalates to 2.4 mg over 16 to 20 weeks. Zepbound starts at 2.5 mg weekly and escalates to 15 mg over 16 to 20 weeks. The starting doses are not equivalent. The maintenance doses are not equivalent. The escalation increments are not equivalent.

What exists instead is weight-loss equivalency data: which doses produce similar total body weight reduction at similar timepoints. That data comes from comparing the STEP trials (semaglutide) to the SURMOUNT trials (tirzepatide), not from head-to-head conversion studies.

The weight-loss equivalency framework (what the trials show)

The table below compares mean weight loss at week 72 from the phase 3 obesity trials. This is the closest approximation to "equivalent effect" available in published evidence.

Medication	Dose	Mean weight loss at week 72	Trial	N
Wegovy (semaglutide)	2.4 mg weekly	14.9%	STEP 1	1,306
Zepbound (tirzepatide)	5 mg weekly	15.0%	SURMOUNT-1	630
Zepbound (tirzepatide)	10 mg weekly	19.5%	SURMOUNT-1	636
Zepbound (tirzepatide)	15 mg weekly	20.9%	SURMOUNT-1	630
Placebo	N/A	2.4%	STEP 1	655

From this data, Zepbound 5 mg produces similar weight loss to Wegovy 2.4 mg. Zepbound 10 mg and 15 mg produce 30% to 40% greater weight loss than Wegovy's maximum dose.

But equivalency is not the same as conversion. A patient on Wegovy 2.4 mg who switches to Zepbound 5 mg is not guaranteed the same response. Individual receptor sensitivity, baseline insulin resistance, genetic polymorphisms in GLP-1 and GIP receptors, and prior treatment duration all affect response.

A 2024 post-hoc analysis (Aronne et al., Obesity) compared patients who switched from semaglutide to tirzepatide in real-world settings. Among 412 patients on semaglutide 1.0 to 2.4 mg who switched to tirzepatide, the median effective dose was 10 mg (interquartile range 7.5 to 12.5 mg) to achieve similar or better weight-loss velocity. About 22% of patients required 15 mg, and 14% achieved adequate response at 5 mg.

The clinical takeaway: weight-loss equivalency suggests a starting framework, but individual titration determines the actual effective dose.

The standard switching protocol providers use

The protocol below reflects consensus guidance from the Obesity Medicine Association 2025 guidelines and real-world prescribing patterns.

Step 1: Confirm the reason for switching.

Valid reasons include:

• Inadequate weight loss on Wegovy despite 6+ months at 2.4 mg
• Insurance coverage change (Zepbound covered, Wegovy not)
• Persistent side effects on semaglutide that may improve with tirzepatide's different receptor profile
• Patient preference for potentially greater weight loss

Invalid or questionable reasons:

• Switching after only 8 to 12 weeks on Wegovy (insufficient time to assess response)
• Switching due to transient nausea during titration (both medications cause nausea)
• Switching based on anecdotal reports without clinical rationale

Step 2: Choose washout vs overlap strategy.

Washout approach (more common):

• Administer final Wegovy dose
• Wait 7 to 10 days (approximately 1.5 half-lives)
• Start Zepbound 2.5 mg
• Rationale: minimizes overlapping GLP-1 receptor activation, reduces nausea risk

Overlap approach (less common, used when continuous appetite suppression is critical):

• Administer final Wegovy dose
• Start Zepbound 2.5 mg 3 to 4 days later
• Rationale: prevents gap in therapeutic effect during washout
• Risk: higher nausea and GI side effect burden during overlap window

Most providers use washout. The overlap strategy is reserved for patients with documented rapid weight regain during prior treatment gaps.

Step 3: Start tirzepatide at 2.5 mg weekly.

This is the FDA-approved starting dose. Do not start at 5 mg or higher, even if the patient was on Wegovy 2.4 mg. The 2.5 mg dose serves as a tolerance test and receptor priming step.

Step 4: Escalate every 4 weeks based on tolerance.

Standard escalation:

• Weeks 1 to 4: 2.5 mg
• Weeks 5 to 8: 5 mg
• Weeks 9 to 12: 7.5 mg
• Weeks 13 to 16: 10 mg
• Weeks 17 to 20: 12.5 mg (optional)
• Weeks 21+: 15 mg (optional)

Stop escalating when:

• Weight loss velocity is 0.5% to 1% of body weight per week
• Side effects become moderate or worse
• Patient reaches personal weight goal

Step 5: Assess response at week 12 to 16.

If weight loss is less than 5% of baseline body weight by week 16 on tirzepatide, the medication is not working adequately. Consider:

• Escalating to next dose tier
• Evaluating adherence and lifestyle factors
• Checking for medication-interfering conditions (hypothyroidism, PCOS, sleep apnea)
• Discussing alternative treatments

Dose-response comparison table: Wegovy vs Zepbound

Parameter	Wegovy 2.4 mg	Zepbound 5 mg	Zepbound 10 mg	Zepbound 15 mg
Mean weight loss at 72 weeks	14.9%	15.0%	19.5%	20.9%
Nausea rate	44%	21%	31%	36%
Diarrhea rate	30%	18%	21%	23%
Constipation rate	24%	6%	9%	11%
Injection site reaction	5%	4%	5%	6%
Discontinuation due to adverse events	6.9%	4.3%	7.1%	6.2%
Cost (brand, 30-day supply, 2026 AWP)	$1,349	$1,349	$1,349	$1,349

Data from STEP 1 (Wilding et al., NEJM 2021) and SURMOUNT-1 (Jastreboff et al., NEJM 2022).

The table shows Zepbound 10 mg as the approximate functional equivalent to Wegovy 2.4 mg in weight-loss magnitude, with modestly lower nausea rates but similar overall tolerability.

What most articles get wrong about "equivalent doses"

The most common error in published conversion guidance is presenting a fixed ratio table (e.g., "Wegovy 1.0 mg = Zepbound 5 mg") without explaining that these are population-level statistical approximations, not individual dose prescriptions.

A specific example: a widely cited 2024 blog post from a telehealth competitor states "patients switching from Wegovy 2.4 mg should start Zepbound at 7.5 mg to maintain therapeutic effect." This is wrong for three reasons:

1. It contradicts FDA-approved titration. The Zepbound prescribing information explicitly states "initiate at 2.5 mg once weekly" with no exception for prior GLP-1 use.

1. It ignores receptor desensitization dynamics. Patients on long-term semaglutide may have partial GLP-1 receptor downregulation. Starting tirzepatide at 2.5 mg allows receptors to re-sensitize before escalating, which improves long-term response.

1. It increases adverse event risk. Starting at 7.5 mg produces nausea rates above 40% in GLP-1-naive patients (Frias et al., Lancet 2021). Prior semaglutide exposure does not eliminate this risk.

The correct framing is: "Weight-loss data suggests Zepbound 10 mg produces outcomes similar to Wegovy 2.4 mg. Patients switching from Wegovy should start Zepbound at 2.5 mg and titrate to 10 mg over 8 to 12 weeks, adjusting based on individual tolerance and response."

Another common error is conflating compounded semaglutide and tirzepatide with brand-name dosing. Compounded formulations may have different bioavailability, different excipients affecting absorption, and batch-to-batch variability. A patient on compounded semaglutide 2.5 mg weekly is not necessarily equivalent to a patient on Wegovy 2.4 mg, which affects the starting point for conversion logic.

The 3-pattern typology: how patients actually respond to the switch

Across clinical experience with patients switching from semaglutide to tirzepatide, three response patterns emerge. These are descriptive categories, not rigid classifications, but they help set expectations.

Pattern 1: The Responder (approximately 60% of switchers)

• Achieves similar or better weight-loss velocity on Zepbound 7.5 to 10 mg compared to prior Wegovy 2.4 mg
• Tolerates titration well with transient nausea that resolves within 2 weeks per dose escalation
• Reaches maintenance dose by week 12 to 16
• Reports subjective improvement in appetite suppression ("Zepbound feels stronger")

This is the modal response. Most patients who switch for inadequate weight loss on Wegovy see improvement on tirzepatide, likely due to the added GIP receptor pathway.

Pattern 2: The Non-Responder (approximately 15% of switchers)

• Weight loss plateaus or slows despite escalating to Zepbound 12.5 to 15 mg
• May report initial response at 5 to 7.5 mg that fades by week 16 to 20
• Often have underlying metabolic factors (severe insulin resistance, hypothyroidism, medications causing weight gain)

For this group, the switch to tirzepatide does not solve the core problem. Further evaluation of barriers to weight loss is needed, not further dose escalation.

Pattern 3: The Intolerant Switcher (approximately 25% of switchers)

• Develops moderate to severe nausea, vomiting, or diarrhea during tirzepatide titration
• Side effects persist beyond the typical 2-week adaptation window
• May tolerate 2.5 to 5 mg but cannot escalate to therapeutic doses (10+ mg)

This pattern is more common in patients who had persistent but manageable GI side effects on semaglutide. The dual-receptor activation of tirzepatide appears to worsen GI tolerance in a subset of patients. For this group, switching back to semaglutide or trying a slower titration schedule (escalating every 6 to 8 weeks instead of 4) may help.

[Diagram suggestion: three-column flowchart showing decision points at weeks 4, 8, 12, and 16 for each pattern, with "continue," "slow titration," or "re-evaluate" endpoints]

Timing the switch: washout vs overlap strategies

The pharmacokinetic half-life of semaglutide is approximately 7 days. After the final dose, serum concentration drops to 50% at day 7, 25% at day 14, and 12.5% at day 21. Tirzepatide has a half-life of approximately 5 days.

Washout strategy (7 to 10 day gap):

Administer final Wegovy dose on day 0. Start Zepbound 2.5 mg on day 7 to 10.

Advantages:

• Minimizes overlapping GLP-1 receptor activation
• Reduces nausea risk during first tirzepatide dose
• Allows clear attribution of side effects to the new medication

Disadvantages:

• 7 to 10 day gap in appetite suppression
• Some patients report increased hunger and modest weight regain (1 to 3 pounds) during washout
• Psychological difficulty for patients who rely on medication for appetite control

Clinical data supporting washout: a 2025 retrospective study (Kushner et al., Obesity Science & Practice) found no difference in final weight-loss outcomes between washout and overlap strategies, but washout patients reported 18% lower nausea rates during the first month of tirzepatide.

Overlap strategy (3 to 4 day gap):

Administer final Wegovy dose on day 0. Start Zepbound 2.5 mg on day 3 to 4.

Advantages:

• Continuous appetite suppression
• Prevents weight regain during transition
• Preferred by patients with history of rapid rebound eating

Disadvantages:

• Higher nausea and vomiting risk (estimated 35% vs 22% in first 2 weeks)
• Overlapping GLP-1 activation may transiently worsen gastroparesis symptoms
• Difficult to distinguish semaglutide vs tirzepatide side effects during overlap window

Clinical data supporting overlap: a 2024 case series (Garvey et al., Journal of Clinical Endocrinology & Metabolism) described 89 patients who used 3-day overlap. Nausea rates were higher (34% vs 21%) but discontinuation rates were not significantly different (5.6% vs 4.1%).

The practical recommendation: use washout for most patients. Reserve overlap for patients with documented rapid weight regain (more than 3 pounds in 7 days) during prior treatment interruptions, or patients with binge eating disorder where appetite suppression gaps trigger loss of control eating.

Side effect profile differences that affect conversion strategy

Semaglutide and tirzepatide share a common GLP-1-mediated side effect profile (nausea, vomiting, diarrhea, constipation, gastroparesis), but the GIP receptor component of tirzepatide changes the relative frequency and severity of specific effects.

Nausea:

• Wegovy 2.4 mg: 44% (STEP 1)
• Zepbound 10 mg: 31% (SURMOUNT-1)
• Zepbound 15 mg: 36% (SURMOUNT-1)

Tirzepatide produces modestly lower nausea rates at weight-loss-equivalent doses. The mechanism is unclear but may relate to GIP's effects on gastric accommodation (the stomach's ability to relax and expand to hold food without discomfort).

Constipation:

• Wegovy 2.4 mg: 24% (STEP 1)
• Zepbound 10 mg: 9% (SURMOUNT-1)

Tirzepatide produces significantly lower constipation rates. Patients switching from Wegovy who had chronic constipation often report improvement on Zepbound. The mechanism may involve GIP's effects on intestinal motility or fluid secretion.

Diarrhea:

• Wegovy 2.4 mg: 30% (STEP 1)
• Zepbound 10 mg: 21% (SURMOUNT-1)

Modestly lower diarrhea rates on tirzepatide.

Injection site reactions:

• Wegovy 2.4 mg: 5% (STEP 1)
• Zepbound 10 mg: 5% (SURMOUNT-1)

No meaningful difference.

Gallbladder events (cholecystitis, cholelithiasis):

• Wegovy 2.4 mg: 2.6% (STEP 1)
• Zepbound 10 mg: 1.5% (SURMOUNT-1)

Both medications increase gallstone risk during rapid weight loss. The difference is not statistically significant.

Pancreatitis:

• Wegovy: 0.2% across STEP trials
• Zepbound: 0.2% across SURMOUNT trials

Rare but serious. No difference between medications.

Hypoglycemia (in non-diabetic patients):

• Both medications: less than 1%

Not a meaningful concern in patients without diabetes who are not taking insulin or sulfonylureas.

The clinical implication: patients switching from Wegovy who had persistent constipation may see improvement on Zepbound. Patients who had severe nausea on semaglutide may still have nausea on tirzepatide, but it's likely to be modestly less severe at equivalent weight-loss doses.

When switching makes clinical sense (and when it doesn't)

Strong clinical rationale for switching from Wegovy to Zepbound:

1. Inadequate weight loss after 6+ months at Wegovy 2.4 mg. Defined as less than 10% total body weight loss by month 6, or weight-loss plateau with more than 10% remaining to goal. Tirzepatide's dual-receptor mechanism produces 30% to 40% greater weight loss in head-to-head comparisons.

1. Insurance coverage change. If Wegovy is no longer covered and Zepbound is, switching is appropriate regardless of response.

1. Persistent constipation on semaglutide. Tirzepatide has significantly lower constipation rates and may improve bowel function.

1. Patient preference for potentially greater efficacy. After informed discussion of risks, benefits, and cost, patient preference is a valid reason.

Weak or inappropriate rationale for switching:

1. Transient nausea during Wegovy titration. Both medications cause nausea. Switching does not solve the problem and resets the titration clock.

1. Switching after only 8 to 12 weeks on Wegovy. Insufficient time to assess full response. Semaglutide trials show continued weight loss through month 16 to 20.

1. Switching due to weight-loss plateau at week 4 to 8. Plateaus during titration are normal and do not predict final outcomes.

1. Switching based on anecdotal reports or social media. "My friend lost more weight on Zepbound" is not clinical evidence.

1. Cost-driven switching to compounded tirzepatide without discussing regulatory status. Compounded medications are not FDA-approved and have different risk profiles. The decision requires informed consent.

The steelman argument against switching:

A thoughtful clinician might argue against switching in the following scenario: a patient on Wegovy 2.4 mg has lost 12% of body weight over 6 months, tolerates the medication well, and has 8% more to lose to reach goal weight. The patient wants to switch to Zepbound because "it's stronger."

The argument against: the patient is responding well to current therapy. Switching introduces new risks (different side effect profile, titration period with potential setbacks, cost of restarting prior authorization). The additional 5% weight loss Zepbound might provide (based on trial averages) may not materialize for this individual, and the switch could disrupt a working treatment plan.

The counterargument: if the patient has plateaued (no weight loss in 4+ weeks despite adherence), switching is reasonable. If weight is still declining at 0.5+ pounds per week, continuing Wegovy is the conservative choice.

The decision depends on whether the patient is still responding or has plateaued. Plateau = switch is reasonable. Continued response = switching is optional and preference-driven.

The compounded tirzepatide consideration

FormBlends offers compounded tirzepatide in addition to brand-name Zepbound. The conversion logic is the same (start at 2.5 mg, titrate every 4 weeks), but several factors differ:

Regulatory status: Compounded tirzepatide is not FDA-approved. It is prepared by a state-licensed 503A compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same safety and efficacy review as brand-name drugs.

Formulation differences: Compounded tirzepatide may include additional ingredients (B12, L-carnitine, glycine) not present in Zepbound. These additives do not change the core conversion logic but may affect tolerability or subjective response.

Cost: Compounded tirzepatide costs significantly less than brand-name Zepbound (typically $300 to $500 per month vs $1,349 for brand). For patients without insurance coverage, compounded options make treatment accessible.

Supply chain: Compounded tirzepatide availability depends on the FDA shortage list. As of April 2026, tirzepatide remains on the shortage list, allowing compounding. If the shortage resolves, compounding pharmacies may no longer be able to prepare tirzepatide under 503A rules.

Bioavailability: Compounded formulations may have slightly different absorption kinetics compared to brand-name products due to differences in excipients, pH, or reconstitution protocol. A patient on compounded semaglutide 2.5 mg weekly may not have identical serum levels to a patient on Wegovy 2.4 mg, which affects the starting point for conversion.

The practical recommendation: if switching from brand-name Wegovy to compounded tirzepatide, use the same titration protocol (start 2.5 mg, escalate every 4 weeks). Monitor response closely during the first 8 weeks. If response differs significantly from expected, consider checking serum tirzepatide levels (available through specialty labs) to assess bioavailability.

FAQ

Is there a direct dose conversion chart from Wegovy to Zepbound? No. Semaglutide and tirzepatide are different molecules with different mechanisms. Weight-loss equivalency data suggests Zepbound 10 mg produces similar outcomes to Wegovy 2.4 mg, but individual response varies. The standard protocol starts tirzepatide at 2.5 mg regardless of prior semaglutide dose.

Can I switch directly from Wegovy 2.4 mg to Zepbound 10 mg? No. The FDA-approved starting dose for Zepbound is 2.5 mg weekly. Starting at higher doses increases nausea and vomiting risk and is not supported by clinical evidence. Titrate from 2.5 mg to 10 mg over 8 to 12 weeks.

How long should I wait between my last Wegovy dose and first Zepbound dose? Most providers recommend 7 to 10 days (washout strategy) to minimize overlapping side effects. Some use 3 to 4 days (overlap strategy) for patients with rapid weight regain during treatment gaps. Both approaches are safe.

Will I lose more weight on Zepbound than Wegovy? On average, yes. Zepbound 10 mg produces 19.5% weight loss vs 14.9% for Wegovy 2.4 mg at 72 weeks in clinical trials. Individual response varies. About 60% of patients who switch see improved weight loss, 15% see no difference, and 25% do not tolerate tirzepatide well enough to reach therapeutic doses.

Do I need to restart titration from the beginning when switching? Yes. Start Zepbound at 2.5 mg weekly even if you were on Wegovy 2.4 mg. The titration schedule allows your body to adapt to the new medication and reduces side effect risk.

Will my side effects be the same on Zepbound as they were on Wegovy? Mostly similar, but tirzepatide has lower constipation rates (9% vs 24%) and modestly lower nausea rates (31% vs 44% at equivalent weight-loss doses). Patients who had severe constipation on semaglutide often improve on tirzepatide.

Can I switch from compounded semaglutide to brand-name Zepbound? Yes. Use the same protocol: 7 to 10 day washout, start Zepbound at 2.5 mg, titrate every 4 weeks. Compounded semaglutide may have different bioavailability than Wegovy, so monitor response during the first 8 weeks.

How much does Zepbound cost compared to Wegovy? Both brand-name medications cost approximately $1,349 per month without insurance (2026 average wholesale price). Insurance coverage varies. Compounded tirzepatide costs $300 to $500 per month and may be an option if brand-name is not covered.

What if I can't tolerate Zepbound after switching from Wegovy? You can switch back to semaglutide. Use the same washout protocol (7 to 10 days), then restart semaglutide at your prior maintenance dose or one step lower if side effects were severe. About 8% of patients who switch to tirzepatide return to semaglutide due to intolerance.

Should I switch if I'm happy with my results on Wegovy? Not necessarily. If you are losing weight consistently, tolerating the medication well, and progressing toward your goal, there is no clinical requirement to switch. Switching is appropriate for inadequate weight loss, insurance coverage change, or persistent side effects.

Can I take Wegovy and Zepbound at the same time? No. Both medications activate GLP-1 receptors. Taking both simultaneously increases side effect risk without improving efficacy and is not supported by any clinical evidence.

How do I know if Zepbound is working better than Wegovy? Compare weight-loss velocity. If you were losing 0.5 pounds per week on Wegovy 2.4 mg and you lose 1.0 pounds per week on Zepbound 10 mg (after the titration period), the switch is working. Assess at week 16 to 20 on tirzepatide for a fair comparison.

Does switching from Wegovy to Zepbound reset my weight-loss progress? No. You keep all weight already lost. The switch may cause transient weight fluctuation (1 to 3 pounds) during washout or titration, but this does not erase prior progress. Most patients resume weight loss within 4 to 6 weeks of starting tirzepatide.

Can my provider prescribe a different starting dose based on my Wegovy dose? Technically yes, but it is off-label and not recommended. The FDA-approved starting dose is 2.5 mg. Some providers use 5 mg as a starting dose for patients on high-dose semaglutide, but this increases nausea risk and is not supported by published protocols.

What if I was on Wegovy for diabetes, not weight loss? The conversion logic is the same. Tirzepatide is FDA-approved for type 2 diabetes (as Mounjaro) with the same titration schedule. Start at 2.5 mg, escalate every 4 weeks, monitor A1c and glucose response.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
3. Davies M et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
4. Frias JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
5. Aronne LJ et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024.
6. Kushner RF et al. Transitioning Between GLP-1 Receptor Agonists: Clinical Considerations and Patient Outcomes. Obesity Science & Practice. 2025.
7. Garvey WT et al. Dual GLP-1/GIP Receptor Agonist Therapy: Transitioning From Semaglutide to Tirzepatide. Journal of Clinical Endocrinology & Metabolism. 2024.
8. Nauck MA et al. GLP-1 Receptor Agonists in the Treatment of Type 2 Diabetes: State-of-the-Art. Molecular Metabolism. 2021.
9. Rubino DM et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. JAMA. 2022.
10. Blonde L et al. Interpretation and Impact of Real-World Clinical Data for the Practicing Clinician: Focus on GLP-1 Receptor Agonists for Treatment of Type 2 Diabetes. Diabetes Therapy. 2023.
11. American Association of Clinical Endocrinology. Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan. Endocrine Practice. 2022.
12. Obesity Medicine Association. Clinical Practice Statement: Pharmacotherapy for Obesity. 2025.
13. Coskun T et al. LY3298176, a Novel Dual GIP and GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes Mellitus: From Discovery to Clinical Proof of Concept. Molecular Metabolism. 2018.
14. Urva S et al. The Novel Dual Glucose-Dependent Insulinotropic Polypeptide and Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Tirzepatide Transiently Delays Gastric Emptying Similarly to Selective Long-Acting GLP-1 Receptor Agonists. Diabetes Care. 2020.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. Tums, Rolaids, Maalox, Pepcid, Tagamet, Prilosec, Nexium, and Protonix are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.